Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- CMIC: Addition of CMIC SS CMO Boosts Sales, Profits
December 3, 2007
- GENERICS NEWS IN BRIEF
December 3, 2007
- EPS: CRO, SMO Businesses Drives Sales, Profits
December 3, 2007
- Gov't Appeals Asserting Legitimacy of Kongo Shinryo
December 3, 2007
- Diovan Remains No.1 for 6th Month in a Row: Rep Track Survey
December 3, 2007
- Kyowa Hakko and Kirin Pharma Are a Perfect Match: Dr Matsuda
December 3, 2007
- Wider Range of Drugs to Be Re-Priced in Next Price Revision
December 3, 2007
- Re-Pricing of ARBs May Be Necessary: Mr Niwa
December 3, 2007
- Nissan Chemical:Pharma Sales Down to \3,415 Mil.
November 26, 2007
- MEDICAL DEVICE NEWS IN BRIEF
November 26, 2007
- Top-4 Wholesalers Keep Operating Profit Rates Above 1%
November 26, 2007
- There Is No Legal Ground for Ban on Kongo Shinryo: Court Ruling
November 26, 2007
- Mediceo Paltac to Expand Its Share on Market for Dispensing Pharmacies
November 26, 2007
- NEW PRODUCTS／POLA Pharma Launches Estradiol Gel
November 26, 2007
- Alfresa: Good Sales to Dispensing Pharmacies Drive Business
November 26, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 26, 2007
- Suzuken: Two-Digit Growth in Sales, Profits
November 26, 2007
- Ono to Minimize Impact of Generics by Further Expanding the Market
November 26, 2007
- Aiming at Launching at Least One Product per Year: Genzyme
November 26, 2007
- Toho Pharm.: Operating Profits Down 1.1% Due to Cost of Distribution Center
November 26, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…